摘要
目的:研究过氧化物酶体增殖物激活受体γ(peroxisome proliferators activated re-ceptor gamma,PPARγ)的特异性配体罗格列酮对人卵巢癌SKOV3细胞中PPARγ和β-catenin表达的影响,并探讨其机制。方法:设立对照组和实验组,采用荧光定量RT-PCR技术和免疫细胞化学方法检测干预前后细胞中PPARγ、β-catenin mRNA和蛋白水平的变化。结果:免疫细胞化学和荧光定量RT-PCR结果显示:SKOV3细胞表达PPARγ,罗格列酮作用于SKOV3细胞24h后PPARγmRNA和蛋白表达水平上调,而β-catenin mRNA和蛋白表达水平下调。结论:罗格列酮通过活化PPARγ,下调β-catenin mRNA和蛋白表达水平,从分子水平上揭示PPARγ可能是基因治疗卵巢癌的理想靶点。
Objective：To study the effect of rosiglitazone （RSG）, a ligand of peroxi- some proliferator-activated receptor gamma（PPARγ） ,on the expression of PPARγ and β-catenin in human ovarian cancer cell line SKOV3 ,and to investigate the mechanism. Methods：The expression of PPARγ, β-catenin mRNA and protein in SKOV3 cells were investigated by RT- PCR and immunocytochemistry, respectively. Results：The results of RT-PCR and immunocyto- chemistry indicated that SKOV3 cells expressed PPARγ/. When SKOV3 ceils were treated with RSG, PPARγ/ mRNA and protein expression was increased, but β-catenin mRNA and protein expression decreased （ P 〈 0.05 ）. Conclusion： The effect of growth inhibition is associated with downregulating expression of β-catenin mRNA and protein via activation of PPARγ/. So it might be one of the ideal strategies for gene therapy of ovarian cancer.
出处
《现代妇产科进展》
CSCD
北大核心
2008年第1期27-30,共4页
Progress in Obstetrics and Gynecology
